Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a new prime contract to provide biomedical preclinical and development capabilities to support the National Institute of Allergy and Infectious Diseases (NIAID). The seven-year, multi-award, indefinite delivery/indefinite quantity contract has an approximate value of up to $545 million across all task areas to be engaged on this program. This project will be funded in whole or in part with federal funds from the NIAID, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021D00030.
Matan Companies chose the right time to enter the life sciences manufacturing sector of real estate. The Frederick-based real estate developer is well on its way to delivering the 2 million square feet of manufacturing space it promised through Progress Labs, a project dedicated exclusively to spec properties for life sciences manufacturing.
Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies
Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies Leidos’s ExGloH Leverages Entrepreneurial Science and Industry-Leading Support Infrastructure to Improve Global Health June [….]